NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

MoonLake Immunotherapeutics (MLTX) Stock Analysis

MoonLake Immunotherapeutics (MLTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MLTX

$10.65

+$0.33 (+3.20%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MLTX with… →

MLTX Key Statistics

As of Oct 21, 2026
Trading
Open
$10.34
Previous Close
$10.32
Day's Range
10.34–10.73
52-Week Range
8.90–23.29
Volume
1.16M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.08
Valuation
Market Cap
$906.39M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.83
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$227.32M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
85.11M
1-Year Return
+16.27%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.51M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MLTX closed at $10.65, +16.27% over 1 year.

MoonLake Immunotherapeutics (MLTX) has a market capitalization of $906.39M.

In fiscal 2025, MLTX reported revenue of $0.00.

MLTX Stock Return by Calendar Year

MoonLake Immunotherapeutics (MLTX) return since Oct 2020: what $10,000 became

1 year
$10,000 $11,627
+16.27%
5 years
$10,000 $10,736
+7.36%
Since Oct 2020
$10,000 $10,153
+1.53%

If you had invested $10,000 in MoonLake Immunotherapeutics (MLTX) at the close on October 20, 2020, the earliest close on record here, it would have been worth $10,153 at the close on October 21, 2026: +1.53% in total, +0.25% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−19.20%
2025−75.66%
2024−10.33%
2023+475.14%
2022+6.17%
2021−13.02%
2020 (partial year)+8.39%

As of October 21, 2026.

MLTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$227.32M—
2024$0.00−$118.94M—
2023$0.00−$36.01M—
2022$0.00−$49.97M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$244.83M−$227.32M—
2024$0.00—−$143.09M−$118.94M—
2023$0.00—−$54.12M−$36.01M—
2022$0.00—−$65.06M−$49.97M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MoonLake Immunotherapeutics (MLTX) carries a market capitalisation of $906.39M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 130 employees.

The 52-week range on file runs from $8.90 to $23.29. MLTX last closed at $10.65 on October 21, 2026. That is +$0.33 (+3.20%) against the previous close. The latest close sits 19.66% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $227.32M. Trailing earnings per share are −3.83.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.08. Annualized volatility over the trailing 6 years is 84.22%. Over the trailing twelve months the total return is +16.27%. Across 5 years the annualized return works out at +1.43%.

Growth & Income

The record shows no dividend for MLTX.

Across the complete calendar years on file, 2023 returned +475.14% and 2025 returned −75.66%. Of the 5 complete calendar years on file, 2 finished higher. So far in 2026 the total return is −19.20%.

Peer Comparison

MoonLake Immunotherapeutics (MLTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MoonLake Immunotherapeutics MLTX $906.39M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. MoonLake Immunotherapeutics has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Visit website →